A Phase 1, Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer

Trial Profile

A Phase 1, Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2017

At a glance

  • Drugs Pixantrone (Primary)
  • Indications Cancer; Lymphoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CTI BioPharma
  • Most Recent Events

    • 14 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 13 Oct 2016 Planned initiation date changed from 1 Aug 2016 to 1 Oct 2016.
    • 20 Jul 2016 Planned initiation date changed from 1 Jun 2016 to 1 Aug 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top